FDA approves higher dosage of naloxone nasal spray to treat opioid overdose

The FDA approved a dose increase to 8 mg (previously 2 mg and 4 mg) on the basis of efficacy and safety data made available. In the UK naloxone spray (Nyxoid) is available as a 1.8 mg intranasal dose, repeatable as necessary whilst waiting for emergency services.

Source:

Biospace Inc.